Starlight Cardiovascular Company Profile

Background

Starlight Cardiovascular, founded in 2020 and headquartered in San Diego, California, is a preclinical-stage medical technology company dedicated to developing minimally invasive devices for pediatric congenital heart disease (CHD). CHD affects approximately 1% of newborns annually, making it the most common birth defect. Starlight's mission is to provide innovative, less invasive treatment options to improve outcomes for these vulnerable patients.

Key Strategic Focus

The company's strategic focus centers on creating a portfolio of interventional cardiology devices tailored to the unique anatomical and physiological needs of pediatric CHD patients. By leveraging advanced technologies, Starlight aims to replace traditional open-chest surgeries with catheter-based procedures, thereby reducing recovery times and long-term developmental risks.

Financials and Funding

Starlight Cardiovascular has secured significant funding to advance its product development:

Series A Financing (October 2022): Raised $9.48 million, led by Bird B, to progress the development of its pediatric interventional cardiology devices.

NIH SBIR Phase II Grants:

March 2023: Awarded $2.16 million from the National Heart, Lung, and Blood Institute (NHLBI) to support preclinical testing of the Ductus Arteriosus Stent System.

May 2024: Received $1.99 million from NHLBI for the development of the Pulmonary Flow Restrictor.

These funds are allocated for design, preclinical testing, and advancing the company's device portfolio toward clinical application.

Pipeline Development

Starlight's product pipeline includes:

Ductus Arteriosus Stent System: A conformable stent designed for pediatric anatomy, delivered via microcatheter, intended to maintain blood flow between pulmonary and systemic circulations in critical CHD cases. Preclinical testing is supported by the March 2023 NIH grant.

Pulmonary Flow Restrictor: A device aimed at preventing excessive pulmonary blood flow in infants with complex CHD, offering a minimally invasive alternative to surgical pulmonary artery banding. Development is funded by the May 2024 NIH grant.

Technological Platform and Innovation

Starlight Cardiovascular distinguishes itself through:

Proprietary Technologies: Development of devices specifically engineered for pediatric patients, addressing the limitations of adult-sized tools used off-label in children.

Scientific Methodologies: Utilization of microcatheter-based delivery systems to enable less invasive procedures, reducing the need for open-chest surgeries in newborns.

Leadership Team

Starlight's leadership comprises experienced professionals:

Beverly Tang, Ph.D. – Co-Founder and Chief Executive Officer. Dr. Tang brings extensive experience in medical device development and strategic leadership.

Thomas Duerig, Ph.D. – Co-Founder and Board Member. Dr. Duerig contributes expertise in biomedical engineering and innovation.

Attila Meretei, M.D. – Co-Founder. Dr. Meretei offers clinical insights into pediatric cardiology.

Carl Berke, Ph.D. – Co-Founder. Dr. Berke provides experience in healthcare investment and technology commercialization.

Pedro del Nido, M.D. – Co-Founder. Dr. del Nido is a renowned pediatric cardiac surgeon contributing clinical expertise.

In June 2023, Paul G. Yock, M.D., founder of the Stanford Byers Center for Biodesign and a pioneer in medical technology innovation, joined the Board of Directors, enhancing the company's strategic direction.

Competitor Profile

Market Insights and Dynamics

The pediatric CHD device market is characterized by a significant unmet need for specialized, minimally invasive solutions. Traditional treatments often involve high-risk surgeries, underscoring the demand for innovative devices tailored to pediatric patients.

Competitor Analysis

Key competitors include:

Edwards Lifesciences: Offers a range of heart valve therapies, including pediatric applications.

Medtronic: Provides various cardiovascular devices, with some products adapted for pediatric use.

These companies primarily focus on adult cardiovascular devices, with limited offerings specifically designed for pediatric patients, highlighting Starlight's niche focus.

Strategic Collaborations and Partnerships

Starlight has established significant partnerships:

Bird B: Led the Series A financing round, providing strategic guidance and support.

National Institutes of Health (NIH): Awarded multiple grants to support the development and preclinical testing of Starlight's devices.

Operational Insights

Starlight's focus on pediatric-specific devices positions it uniquely in the market. By addressing the limitations of adult-sized tools used off-label in children, the company offers innovative solutions that cater directly to the needs of pediatric CHD patients.